PPARG and pulmonary fibrosis: We previously demonstrated that a PPARγ antagonist (GW9662) can reverse the enhanced efferocytosis, reduced pro-inflammatory cytokine expression, and neutrophil recruitment into the lung following apoptotic cell instillation in lung fibrosis [33].